Clinical TrialJul 8, 2026, 06:32 AM
Satellos SAT-3247 Shows Positive 6-Month TRAILHEAD Data in DMD Adults
AI Summary
Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for SAT-3247 in adults with Duchenne muscular dystrophy (DMD). The investigational drug showed reduced muscle fat fraction, increased total effort, stable strength, and lower creatine kinase (CK) levels. The safety profile remained favorable and consistent with previous reports, with all four participants showing improvements in key metrics despite the advanced stage of their disease. The company plans to complete enrollment in the BASECAMP study and initiate US clinical trial sites for TRAILHEAD in Q3.
Key Highlights
- Muscle fat fraction declined by a mean of 3.7% in all four participants.
- Upper limb effort (TE99C) increased by approximately 34% in all four participants.
- Near-doubling of handgrip strength from CL-101 study was maintained through 6 months.
- Mean creatine kinase (CK) declined 38% from baseline through 6 months.
- PUL2.0 increased by one point in two participants and remained stable in two.
- PedsQL-MFS scores increased 6.94 points from CL-101 baseline to month 6.
- 100% compliance over an average of 186 days of drug exposure.
Price Impact
More from MSLE